Skye Bioscience, Inc. (SKYE) stock
SKYENasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.08+0.16 (+17.52%)
Close on Nov 12, 2026Market cap $38.26MP/E –Yield –
Skye Bioscience enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Skye Bioscience's enterprise value was $22.23M on Nov 11, 2026, against $289.45M a year earlier. Over the last 5 years it ranged from $22.23M to $2.52B, with a median of $177.72M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $22.23M | -85.2% |
| 2025 | Dec 31, 2025 | $150.55M | -75.7% |
| 2024 | Dec 31, 2024 | $619.45M | +130.7% |
| 2023 | Dec 29, 2023 | $268.49M | +325.8% |
| 2022 | Dec 30, 2022 | $63.06M | -66.3% |
| 2021 | Dec 31, 2021 | $186.97M | +146.4% |
| 2020 | Dec 31, 2020 | $75.87M | -45.5% |
| 2019 | Dec 31, 2019 | $139.21M | -67.3% |
| 2018 | Dec 31, 2018 | $425.96M | +1043.5% |
| 2017 | Dec 29, 2017 | $37.25M | -22.1% |
| 2016 | Dec 30, 2016 | $47.79M | -50.7% |
| 2015 | Dec 31, 2015 | $96.90M | – |
See a number that looks wrong?